{
  "main_header": {
    "sid": 10038997,
    "name": "Saroja Pharma In",
    "stock_name": "Saroja Pharma In",
    "full_name": "Saroja Pharma Industries India Ltd",
    "name_url": "stocks-analysis/saroja-pharma-in",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "40.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "40.00",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "SAROJA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0PCL01011",
    "curr_date": "Dec 23",
    "curr_time": "",
    "bse_nse_vol": 3200,
    "exc_status": "Active",
    "traded_date": "Dec 23, 2025",
    "traded_date_str": "2025 12 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/saroja-pharma-in-10038997-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3757873",
        "imagepath": "",
        "date": "2025-12-13 01:24:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>While the stock has delivered a robust one-week return of 9.14%, comfortably outpacing the Sensex’s marginal decline of 0.53% over the same period, the year-to-date performance paints a contrasting picture. Saroja Pharma’s shares have declined by 28.33% since the start of the year, markedly underperforming the Sensex, which has gained 10.16% in that timeframe. Over the past year, the stock has similarly lagged, falling 23.15% against the Sensex’s 6.10% rise. This divergence suggests that despite short-term rallies, the stock remains under pressure from longer-term headwinds.</p>\n<p><strong>Technical Indicators and Investor Participation</strong></p>\n<p>Examining the technical landscape reveals a nuanced scenario. The current price of ₹..."
      },
      {
        "title": "How has been the historical performance of Saroja Pharma In?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-saroja-pharma-in-3699805",
        "imagepath": "",
        "date": "2025-11-13 23:51:10",
        "description": "Answer:\nThe historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years.\n\nBreakdown:\nSaroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 ..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3691422",
        "imagepath": "",
        "date": "2025-11-12 00:10:32",
        "description": "As of 11-Nov, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 41.25, which reflects a decrease of 1.9 or 4.4%. The stock has underperformed its sector by 4.27% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 66.67% compared to the 5-day average. Over the past week, the stock has decreased by 4.40%, and it has also shown a substantial decline of 31.25% year-to-date, indicating ongoing challenges for the company.\n\nIn the broader market context, while Saroja Pharma's stock has fallen significantly, the benchmark Sensex has shown a slight increase of 0.38% over the past week and a gain of 8.67% year-to-date. This stark contrast highlights the stock's underperformance relative to the market. The overall negative sentim..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3636367",
        "imagepath": "",
        "date": "2025-10-20 23:11:58",
        "description": "As of 20-Oct, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 43.60, which reflects a decrease of 2.0 or 4.39%. The stock has underperformed its sector by 5.07% today, and while it is higher than the 100-day moving average, it is lower than the 5-day, 20-day, 50-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.43%, and year-to-date, it has decreased by 27.33%. Notably, there has been a significant rise in investor participation, with delivery volume increasing by 233.33% against the 5-day average, indicating some interest despite the overall negative performance. Unfortunately, there is no available information regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Saroja Pharma's short-term performance has been notably weaker compared to the benchmark Sensex,..."
      },
      {
        "title": "Is Saroja Pharma In overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-saroja-pharma-in-overvalued-or-undervalued-3597238",
        "imagepath": "",
        "date": "2025-10-07 08:06:10",
        "description": "As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation.\n\nGiven these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price o..."
      },
      {
        "title": "Is Saroja Pharma In overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-saroja-pharma-in-overvalued-or-undervalued-3592451",
        "imagepath": "",
        "date": "2025-10-06 08:05:14",
        "description": "As of 3 October 2025, Saroja Pharma's valuation grade has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 16.71, a Price to Book Value of 1.10, and an EV to EBITDA ratio of 8.84. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.04, indicating it is expensive, while Dr. Reddy's Labs, which is considered attractive, has a PE ratio of 18.34.\n\nSaroja Pharma's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 0.98, indicating potential growth relative to its earnings. However, the company's stock has underperformed against the Sensex, with a year-to-date return of -28.67% compared to the Sensex's 5.28%. This performance may reflect market sentiment rather than the underlying valuation, reinforcing the view that Saroja Pharma is fairly valued at its current price of 42.80...."
      }
    ],
    "total": 63,
    "sid": "10038997",
    "stock_news_url": "https://www.marketsmojo.com/news/saroja-pharma-industries-india-10038997"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Saroja Pharma In falling/rising?

2025-12-13 01:24:36

Recent Price Movement and Market Context

While the stock has delivered a robust one-week return of 9.14%, comfortably outpacing the Sensex’s marginal decline of 0.53% over the same period, the year-to-date performance paints a contrasting picture. Saroja Pharma’s shares have declined by 28.33% since the start of the year, markedly underperforming the Sensex, which has gained 10.16% in that timeframe. Over the past year, the stock has similarly lagged, falling 23.15% against the Sensex’s 6.10% rise. This divergence suggests that despite short-term rallies, the stock remains under pressure from longer-term headwinds.

Technical Indicators and Investor Participation

Examining the technical landscape reveals a nuanced scenario. The current price of ₹...

Read More

How has been the historical performance of Saroja Pharma In?

2025-11-13 23:51:10

Answer: The historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years. Breakdown: Saroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 ...

Read More

Why is Saroja Pharma In falling/rising?

2025-11-12 00:10:32

As of 11-Nov, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 41.25, which reflects a decrease of 1.9 or 4.4%. The stock has underperformed its sector by 4.27% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 66.67% compared to the 5-day average. Over the past week, the stock has decreased by 4.40%, and it has also shown a substantial decline of 31.25% year-to-date, indicating ongoing challenges for the company. In the broader market context, while Saroja Pharma's stock has fallen significantly, the benchmark Sensex has shown a slight increase of 0.38% over the past week and a gain of 8.67% year-to-date. This stark contrast highlights the stock's underperformance relative to the market. The overall negative sentim...

Read More

Why is Saroja Pharma In falling/rising?

2025-10-20 23:11:58

As of 20-Oct, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 43.60, which reflects a decrease of 2.0 or 4.39%. The stock has underperformed its sector by 5.07% today, and while it is higher than the 100-day moving average, it is lower than the 5-day, 20-day, 50-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.43%, and year-to-date, it has decreased by 27.33%. Notably, there has been a significant rise in investor participation, with delivery volume increasing by 233.33% against the 5-day average, indicating some interest despite the overall negative performance. Unfortunately, there is no available information regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Saroja Pharma's short-term performance has been notably weaker compared to the benchmark Sensex,...

Read More

Is Saroja Pharma In overvalued or undervalued?

2025-10-07 08:06:10

As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation. Given these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price o...

Read More

Is Saroja Pharma In overvalued or undervalued?

2025-10-06 08:05:14

As of 3 October 2025, Saroja Pharma's valuation grade has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 16.71, a Price to Book Value of 1.10, and an EV to EBITDA ratio of 8.84. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.04, indicating it is expensive, while Dr. Reddy's Labs, which is considered attractive, has a PE ratio of 18.34. Saroja Pharma's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 0.98, indicating potential growth relative to its earnings. However, the company's stock has underperformed against the Sensex, with a year-to-date return of -28.67% compared to the Sensex's 5.28%. This performance may reflect market sentiment rather than the underlying valuation, reinforcing the view that Saroja Pharma is fairly valued at its current price of 42.80....

Read More

View All News